 |
- Member of the scientific advisory board of Corcept
Therapeutics—a company carrying out trials with mifepristone,
which was mentioned favourably in the review—and, as such, was
given an option to purchase 72 000 shares at a total cost of
$21.60
- Director and chairman of the psychopharmacology advisory
board of Cypress Bioscience, which has only one product—milnacipran—which
was mentioned in the review
|
